Shares of WuXi Biologics surged 7.2% to HK$47.68 on November 3 after the contract drugmaker announced an exclusive decade-long development pact with Germany's Fresenius — described as the largest development agreement in the biosimilars industry to date . For a company still navigating U.S. political risk, the deal sends a clear signal: WuXi's manufacturing muscle remains in high demand.
Up to 37 New Molecules Could More Than Double Fresenius's Portfolio
Under the agreement, Fresenius gains exclusive access to up to 37 identified biosimilar candidates, expanding its current portfolio of 29 marketed and pipeline molecules to as many as 66 products . The candidates span monoclonal and bispecific antibodies, antibody-drug conjugates, and fusion proteins — precisely the complex biologics where WuXi's expertise commands premium pricing. The 37 candidates address more than €370 billion ($414 billion) in originator sales , underscoring the sheer revenue pool at stake for Fresenius downstream.
WuXi Gets Steady Fees, Not Blockbuster Upside
WuXi Biologics will be compensated on a fee-for-service basis for each biosimilar candidate selected for development , while Fresenius retains exclusive global commercialization rights and full economic ownership . Translation: WuXi earns predictable revenue as each molecule enters its labs, but won't share in product sales. That limits the profit ceiling per molecule, yet adds a layer of revenue visibility on top of a backlog already at US$25.1 billion as of June 30, including $5.5 billion due within three years .
The Deal Lands in a Fast-Growing Market — With a Political Asterisk The global biosimilars market is expanding rapidly — projected to grow at roughly 17% annually through 2034 — fueled by waves of blockbuster biologic patent expiries. WuXi is well-positioned to ride that wave. Yet the shadow of the U.S. BIOSECURE Act lingers. WuXi Biologics is not currently designated a "biotechnology company of concern" , but parent company WuXi AppTec was added to the DoD's 1260H list , keeping regulatory risk alive. The Fresenius deal — a European anchor client — diversifies that exposure.
Revenue Momentum Was Already Strong Before This Catalyst
H1 2026 revenue rose 18.4% year-over-year to RMB 11.8 billion, and management raised guidance, projecting a 20% revenue compound annual growth rate over the next three years . Adding up to 37 fee-generating programs bolsters that trajectory, though the "up to" language means molecule selection — and timing — remains at Fresenius's discretion. Investors should watch for project-start disclosures in coming quarters to gauge how quickly this deal converts headline promise into booked revenue.